Skip to main content
Erschienen in: World Journal of Surgery 3/2009

01.03.2009

Comparison of Ex Vivo and In Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colorectal Cancer

verfasst von: Jun Seok Park, In Taik Chang, Sung Jun Park, Beom Gyu Kim, Yoo Shin Choi, Seong Jae Cha, Eon Sub Park, Gui Young Kwon

Erschienen in: World Journal of Surgery | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The technique of sentinel lymph node (SLN) mapping in patients with colorectal cancer varies between reports, and the optimal method has not been established. The purpose of this study was to determine the optimal injection technique for SLN mapping.

Methods

Sixty-nine consecutive patients who underwent curative surgery for colorectal cancer were enrolled. The SLNs was identified intraoperatively by subserosal blue dye injection (in vivo) or by submucosal injection after standard colectomy (ex vivo). If negative by conventional hematoxylin and eosin staining analysis, all lymph nodes, SLNs and non-SLNs, were subjected to further analysis by multi-level section and immunohistochemical examination.

Results

The in vivo and ex vivo injected groups were similar in demographic character, tumor size, and histological grade. The mean number of SLNs identified was 2.3 in the in vivo group and 2.6 in the ex vivo group (p = 0.192). The detection rate of SLNs by blue dye injection was somewhat higher in the ex vivo group than in the in vivo group: 90.6 vs. 81.1% (p = 0.219). The false-negative rate was 23.5% for the in vivo group and 13.3% for the ex vivo group (p = 0.392). The upstaging rate, which was 18.5% overall, was similar in both groups (p = 0.538).

Conclusions

These findings suggest that ex vivo blue dye injection is an effective alternative to in vivo injection for identifying SLNs in patients with colorectal cancer. Because of its simplicity and applicability in routine clinical settings, further investigation of the ex vivo mapping technique is warranted.
Literatur
1.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed
2.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. Clin Oncol 13:2936–2943 Moertel CG, Fleming TR, Macdonald JS (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. Clin Oncol 13:2936–2943
3.
Zurück zum Zitat International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356–1363 International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356–1363
4.
Zurück zum Zitat Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
5.
Zurück zum Zitat Cohen AM, Tremiterra S, Candela F et al (1991) Prognosis of node-positive colon cancer. Cancer 67:1859–1861PubMedCrossRef Cohen AM, Tremiterra S, Candela F et al (1991) Prognosis of node-positive colon cancer. Cancer 67:1859–1861PubMedCrossRef
6.
Zurück zum Zitat Bilchik AJ, Hoon DS, Saha S et al (2007) Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg 246:568–575PubMedCrossRef Bilchik AJ, Hoon DS, Saha S et al (2007) Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg 246:568–575PubMedCrossRef
7.
Zurück zum Zitat Saha S, Wiese D, Badin J et al (2000) Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging. Ann Surg Oncol 7:120–124PubMedCrossRef Saha S, Wiese D, Badin J et al (2000) Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging. Ann Surg Oncol 7:120–124PubMedCrossRef
8.
Zurück zum Zitat Wong JH, Steineman S, Calderia C et al (2001) Ex vivo sentinel node mapping in carcinoma of the colon and rectum. Ann Surg 233:515–521PubMedCrossRef Wong JH, Steineman S, Calderia C et al (2001) Ex vivo sentinel node mapping in carcinoma of the colon and rectum. Ann Surg 233:515–521PubMedCrossRef
9.
Zurück zum Zitat Wood TF, Saha S, Morton DL et al (2001) Validation of lymphatic mapping in colorectal cancer: in vivo, ex vivo, and laparoscopic techniques. Ann Surg Oncol 8:150–157PubMedCrossRef Wood TF, Saha S, Morton DL et al (2001) Validation of lymphatic mapping in colorectal cancer: in vivo, ex vivo, and laparoscopic techniques. Ann Surg Oncol 8:150–157PubMedCrossRef
10.
Zurück zum Zitat Saha S, Dan AG, Berman B et al (2004) Lymphazurin 1% versus 99mTc sulfur colloid for lymphatic mapping in colorectal tumors: a comparative analysis. Ann Surg Oncol 11:21–26PubMedCrossRef Saha S, Dan AG, Berman B et al (2004) Lymphazurin 1% versus 99mTc sulfur colloid for lymphatic mapping in colorectal tumors: a comparative analysis. Ann Surg Oncol 11:21–26PubMedCrossRef
11.
Zurück zum Zitat Read TE, Fleshman JW, Caushaj PF (2005) Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum 48:80–85PubMedCrossRef Read TE, Fleshman JW, Caushaj PF (2005) Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum 48:80–85PubMedCrossRef
12.
Zurück zum Zitat Bertagnolli M, Miedema B, Redston M et al (2004) Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 240:624–628PubMed Bertagnolli M, Miedema B, Redston M et al (2004) Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 240:624–628PubMed
13.
Zurück zum Zitat Dahl K, Westlin J, Kraaz W et al (2005) Identification of sentinel nodes in patients with colon cancer. Eur J Surg Oncol 31:381–385PubMedCrossRef Dahl K, Westlin J, Kraaz W et al (2005) Identification of sentinel nodes in patients with colon cancer. Eur J Surg Oncol 31:381–385PubMedCrossRef
14.
Zurück zum Zitat Tuech JJ, Pessaux P, Regenet N et al (2004) Sentinel lymph node mapping in colon cancer. Surg Endosc 18:1721–1729PubMedCrossRef Tuech JJ, Pessaux P, Regenet N et al (2004) Sentinel lymph node mapping in colon cancer. Surg Endosc 18:1721–1729PubMedCrossRef
15.
Zurück zum Zitat Bembenek AE, Rosenberg R, Wagler E et al (2007) Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg 245:858–863PubMedCrossRef Bembenek AE, Rosenberg R, Wagler E et al (2007) Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg 245:858–863PubMedCrossRef
16.
Zurück zum Zitat Yagci G, Unlu A, Kurt B et al (2007) Detection of micrometastases and skip metastases with ex vivo sentinel node mapping in carcinoma of the colon and rectum. Int J Colorectal Dis 22:167–173PubMedCrossRef Yagci G, Unlu A, Kurt B et al (2007) Detection of micrometastases and skip metastases with ex vivo sentinel node mapping in carcinoma of the colon and rectum. Int J Colorectal Dis 22:167–173PubMedCrossRef
17.
Zurück zum Zitat Tuech JJ, Pessaux P, Di Fiore F et al (2006) Sentinel node mapping in colon carcinoma: in-vivo versus ex-vivo approach. Eur J Surg Oncol 32:158–161PubMedCrossRef Tuech JJ, Pessaux P, Di Fiore F et al (2006) Sentinel node mapping in colon carcinoma: in-vivo versus ex-vivo approach. Eur J Surg Oncol 32:158–161PubMedCrossRef
18.
Zurück zum Zitat Saha S, Seghal R, Patel M et al (2006) A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg 191:305–310PubMedCrossRef Saha S, Seghal R, Patel M et al (2006) A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg 191:305–310PubMedCrossRef
19.
Zurück zum Zitat Bilchik AJ, Saha S, Wiese D et al (2001) Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol 19:1128–1136PubMed Bilchik AJ, Saha S, Wiese D et al (2001) Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol 19:1128–1136PubMed
20.
Zurück zum Zitat Faerden AE, Sjo O, Andersen SN et al (2008) Sentinel node mapping does not improve staging of lymph node metastasis in colonic cancer. Dis Colon Rectum 51:891–896PubMedCrossRef Faerden AE, Sjo O, Andersen SN et al (2008) Sentinel node mapping does not improve staging of lymph node metastasis in colonic cancer. Dis Colon Rectum 51:891–896PubMedCrossRef
21.
Zurück zum Zitat Redston M, Compton CC, Miedema BW et al (2006) Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol 24:878–883PubMedCrossRef Redston M, Compton CC, Miedema BW et al (2006) Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol 24:878–883PubMedCrossRef
22.
Zurück zum Zitat Bilchik AJ, DiNome M, Saha S et al (2006) Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg 141:527–533PubMedCrossRef Bilchik AJ, DiNome M, Saha S et al (2006) Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg 141:527–533PubMedCrossRef
23.
Zurück zum Zitat Stojadinovic A, Nissan A, Protic M et al (2007) Prospective randomized study comparing sentinel lymph node evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI–01. Ann Surg 245:846–857PubMedCrossRef Stojadinovic A, Nissan A, Protic M et al (2007) Prospective randomized study comparing sentinel lymph node evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI–01. Ann Surg 245:846–857PubMedCrossRef
24.
Zurück zum Zitat Stojadinovic A, Allen PJ, Protic M et al (2005) Colon sentinel lymph node mapping: practical surgical applications. J Am Coll Surg 201:297–313PubMedCrossRef Stojadinovic A, Allen PJ, Protic M et al (2005) Colon sentinel lymph node mapping: practical surgical applications. J Am Coll Surg 201:297–313PubMedCrossRef
25.
Zurück zum Zitat Wong JH, Johnson DS, Namiki T et al (2004) Validation of ex vivo lymphatic mapping in hematoxylin-eosin node-negative carcinoma of the colon and rectum. Ann Surg Oncol 11:772–777PubMedCrossRef Wong JH, Johnson DS, Namiki T et al (2004) Validation of ex vivo lymphatic mapping in hematoxylin-eosin node-negative carcinoma of the colon and rectum. Ann Surg Oncol 11:772–777PubMedCrossRef
26.
Zurück zum Zitat van Schaik PM, van der Linden JC, Ernst MF et al (2007) Ex vivo sentinel lymph node “mapping” in colorectal cancer. Eur J Surg Oncol 33:1177–1182PubMed van Schaik PM, van der Linden JC, Ernst MF et al (2007) Ex vivo sentinel lymph node “mapping” in colorectal cancer. Eur J Surg Oncol 33:1177–1182PubMed
27.
Zurück zum Zitat Demirbaş S, Ince M, Baloğlu H et al (2004) Should sentinel lymph node mapping be performed for colorectal cancer? Turk J Gastroenterol 15:39–44PubMed Demirbaş S, Ince M, Baloğlu H et al (2004) Should sentinel lymph node mapping be performed for colorectal cancer? Turk J Gastroenterol 15:39–44PubMed
28.
Zurück zum Zitat Baton O, Lasser P, Sabourin JC et al (2005) Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg 29:1166–1170PubMedCrossRef Baton O, Lasser P, Sabourin JC et al (2005) Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg 29:1166–1170PubMedCrossRef
29.
Zurück zum Zitat Smith FM, Coffey JC, Khasri NM et al (2005) Sentinel nodes are identifiable in formalin-fixed specimens after surgeon-performed ex vivo sentinel lymph node mapping in colorectal cancer. Ann Surg Oncol 12:504–509PubMedCrossRef Smith FM, Coffey JC, Khasri NM et al (2005) Sentinel nodes are identifiable in formalin-fixed specimens after surgeon-performed ex vivo sentinel lymph node mapping in colorectal cancer. Ann Surg Oncol 12:504–509PubMedCrossRef
30.
Zurück zum Zitat Bembenek A, Rau B, Moesta T et al (2004) Sentinel lymph node biopsy in rectal cancer—not yet ready for routine clinical use. Surgery 135:498–505PubMedCrossRef Bembenek A, Rau B, Moesta T et al (2004) Sentinel lymph node biopsy in rectal cancer—not yet ready for routine clinical use. Surgery 135:498–505PubMedCrossRef
31.
Zurück zum Zitat Thevarajah S, Huston TL, Simmons RM (2005) A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 189:236–239PubMedCrossRef Thevarajah S, Huston TL, Simmons RM (2005) A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg 189:236–239PubMedCrossRef
32.
Zurück zum Zitat Simmons R, Thevarajah S, Brennan MB et al (2003) Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol 10:242–247PubMedCrossRef Simmons R, Thevarajah S, Brennan MB et al (2003) Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol 10:242–247PubMedCrossRef
33.
Zurück zum Zitat Borgstein PJ, Pijpers R, Comans EF et al (1998) Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186:275–283PubMedCrossRef Borgstein PJ, Pijpers R, Comans EF et al (1998) Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186:275–283PubMedCrossRef
34.
Zurück zum Zitat Iddings D, Ahmad A, Elashoff D et al (2006) The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 13:1386–1392PubMedCrossRef Iddings D, Ahmad A, Elashoff D et al (2006) The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 13:1386–1392PubMedCrossRef
Metadaten
Titel
Comparison of Ex Vivo and In Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colorectal Cancer
verfasst von
Jun Seok Park
In Taik Chang
Sung Jun Park
Beom Gyu Kim
Yoo Shin Choi
Seong Jae Cha
Eon Sub Park
Gui Young Kwon
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 3/2009
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-008-9872-6

Weitere Artikel der Ausgabe 3/2009

World Journal of Surgery 3/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.